Log In
Print this Print this

Biosimilar agalsidase beta (ISU303)

  Manage Alerts
Collapse Summary General Information
Company Isu Abxis Co. Ltd.
DescriptionBiosimilar of fabrazyme
Molecular Target
Mechanism of ActionEnzyme replacement therapy; Biosimilar
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationFabry's disease
Indication DetailsTreat Fabry's disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today